You are here
Large Volume Wearable Injectors Market
Driven by a growing pipeline of drugs targeting various chronic disorders, the large volume wearable injectors market is anticipated to grow at a rapid pace (CAGR ~40%), predicts Roots Analysis
Roots Analysis has announced the addition of “Large Volume Wearable Injectors Market (4th Edition), 2018-2030” report to its list of offerings.
Harsimran Kaur, the principal analyst, stated, “The large volume wearable injectors continue to retain the interest of both drug developers and medical device manufacturers. This can be attributed to the various benefits offered by these devices. In fact, over 50 devices are currently under development / approved for the delivery of both insulin and non-insulin drugs.”
The report presents opinions on several key aspects of the market. Among other elements, it includes:
- A detailed review of the overall landscape of the large volume wearable injectors market, highlighting the contributions of industry players related to the delivery of both insulin and non-insulin drugs, along with key device specifications. It is worth highlighting that devices designed for administration of non-insulin drugs have a high storage capacity and are being developed for delivery of high viscosity formulations. In fact, around 17% of such devices have been designed to hold 10-15 ml of drug formulation, while 23% claim to offer a maximum storage capacity of more than 15 ml.
- A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs). Close to 80 drug / drug candidates demonstrate the potential to be delivered via large volume wearable injectors and are likely to be evaluated in different drug-device combinations in the near future. Of these, 90% are biologics and 10% are small molecules. These drugs (full list available in the main report) are designed for treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems.
- A comprehensive product competitiveness analysis of all large volume wearable injectors, taking into consideration the supplier power (based on the year of establishment) and product specifications, such as type of device, type of dose, maximum volume of the device, usability, allowed route of administration, connectivity with the mobile application, and availability of an integrated continuous glucose monitoring / blood glucose monitoring (CGM / BGM) system in case of insulin devices.
- Elaborate profiles of prominent product developers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and a comprehensive future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products. More than 10 drug device combinations are currently being evaluated for delivery of non-insulin drugs. Of these, two are already approved by the USFDA; these are Neulasta® (pegfilgrastim) OnPro™ Kit (Amgen / Insulet) and Pushtronex™ System (Amgen / West Pharmaceuticals).
- An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors, since 1984. It also highlights the key parameters associated with the patents, including information on patent type, patent offices, Cooperative Patent Classification (CPC) classification, emerging areas (in terms of number of patents filed / granted) and leading industry players (in terms of size of intellectual property portfolio). Close to 2,000 patents pertaining to these devices have been filed till September 2018. An analysis of these patents reveals that automated self-injection devices, with advanced features, are gradually gaining traction amongst patients with chronic disorders.
- A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis is based on tweets posted on the platform from 2013 to 2018.
- A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of wearable injectors. The study includes short descriptions of the manufacturing services provided by contract service providers in the manufacturing of various device components (primary containers), infusion sets, adhesives, closures and injection moldingss.
Street name: A430, 4th Floor, Bestech Business Towers, Sector 66,
Pin Code: 160059
Contact Number: +14158003415
We provide market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis covering the following parameters:
Research and development
Existing market landscape
Future Commercial potential
Regional growth drivers
Risks and opportunities
We specialise in analysing areas which have lacked quality research so far or require more focussed understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.